Discover how dose adjustments of Cabozantinib for toxicity impact its effectiveness in treating metastatic Renal Cell Carcinoma, as revealed by the latest findings from the Canadian Kidney Cancer Information System.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Graham et al., Clin Genitourin Cancer 2024
<!– DOI: 10.1016/j.clgc.2024.02.011 //–>
https://doi.org/10.1016/j.clgc.2024.02.011
This study explores the relationship between dose reductions of cabozantinib, a tyrosine kinase inhibitor used in metastatic renal cell carcinoma (mRCC), and clinical outcomes. Analyzing data from the CKCis database covering 2011 to 2021, researchers divided 319 patients into two groups based on whether they underwent dose reductions (DR) due to toxicity or not (no-DR). The findings reveal no significant difference in objective response rates between the two groups. However, those in the DR group showed notably better median overall survival (OS) of 26.15 months compared to 15.47 months in the no-DR group, and longer time to treatment failure (TTF) of 12.74 months versus 6.44 months. These outcomes remained significant after adjusting for risk factors, suggesting that dose reductions, as a marker of toxicity and drug exposure, could be a valuable indicator for optimizing treatment effectiveness. The study calls for further research to confirm these results and to potentially guide individualized dosing strategies, especially when cabozantinib is used alone or with immunotherapy.